qq.com
Lv4
565 积分
2020-11-23 加入
-
CSCO 原发性肝癌诊疗指南(2024)
2天前
已完结
-
NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. V3, 2024
2天前
求助中
-
胸腺肽α1对围手术期胰腺癌患者血中T和NK细胞的影响
15天前
已完结
-
复发性子宫内膜癌的治疗
22天前
已完结
-
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
30天前
已完结
-
Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Within the Milan Criteria
1个月前
已完结
-
肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)
1个月前
已完结
-
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score
2个月前
已关闭
-
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
-
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66
2个月前
已完结